Please see new guidance from the UK Chemotherapy Board on ‘Personalised Medicine Approach For Fluoropyrimidine-based Therapies’.
Objective of document: To provide clinical staff with guidance as to which patients should receive a DPD test and then subsequently to provide advice to clinical staff on the outcome of that test.
Full guidance can be accessed HERE or found in our resource center in the BOPA website.
We are pleased to announce that BOPA Fellowship Nominations have now opened for 2026. The BOPA Fellowship Scheme Policy has been updated for a clearer nomination and selection process including specific criteria for assessing…
Expressions of interest: We are currently seeking expressions of interest to support an exciting new project with the Pharmaceutical Press (PhP). PhP is developing a new resource to support healthcare…
Abstract Submission for the 29th Annual BOPA Conference 2026 is now OPEN Deadline for Abstract Submission for the 29th Annual BOPA Conference 2026 has been EXTENDED! Don’t miss the…
BOPA are offering (in collaboration with Gilead) 16 funded places to the BOPA 2026 Conference in London from 2-4th Oct 20265. Information can be found here – The BOPA Training and Development Grant…
The 29th BOPA Annual Conference in 2026 will be held at the ICC London Olympia on 2-4 October 2026.
Check out the latest information here: Latest Conference 2026 – BOPA
Everything you need to know
